Giving Nivolumab/Ipilimumab First Ups Overall Survival in Melanoma

Source: Health Day, December 2021

WEDNESDAY, Dec. 1, 2021 (HealthDay News) — For patients with advanced BRAF V600-mutant metastatic melanoma, overall survival (OS) is superior with a treatment sequence beginning with nivolumab/ipilimumab (N/I), according to a study presented Nov. 16 at the inaugural American Society of Clinical Oncology Virtual Plenary Series.

Michael B. Atkins, M.D., from the Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., and colleagues compared the efficacy and toxicity of the sequence of N/I followed by dabrafenib/trametinib (D/T) or the converse sequence for patients with treatment-naive BRAF V600-mutant metastatic melanoma. Patients were randomly assigned to receive step 1 with N/I (arm A; 133 patients) or D/T (arm B; 132 patients) and at disease progression were enrolled in step 2 for alternate therapy: D/T (arm C) or N/I (arm D).

READ THE ORIGINAL FULL ARTICLE
Menu